DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for acute myocardial infarction — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcute myocardial infarction maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acute myocardial infarction is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
Thrombolytic therapy, introduced intravenously, changed the management of acute myocardial infarction by re-establishing coronary artery patency, though patency failures and re-occlusions remained problems with the established agents. By 2003, novel thrombolytic drugs were being developed and evaluated, and adjunctive therapies were under discussion, but no concrete survival or response rates are given in that review.
A 2020 viewpoint notes that atherosclerosis, the main cause of acute myocardial infarction, is an inflammatory disease. Risk factors such as hypertension, diabetes, smoking, dyslipidaemia, obesity, emotional stress and family history are not sufficient for in-hospital risk assessment. The abstract mentions haematological parameters as potentially relevant but provides no numerical results, no sample sizes, and no evidence of benefit from any specific intervention.
A 2024 review states that current clinical guidelines were formed at the end of the first decade of the 21st century and have seen no principal changes since, due to a lack of fundamentally new approaches. Compliance with these guidelines has reduced hospital mortality and improved long-term outcomes, but absolute hospital mortality rates for acute myocardial infarction remain quite high, and long-term prognosis is very unfavourable. The review analyses major randomised clinical trials that ended in 2023–2024 and studied fundamentally new approaches; none gave a positive result. A new trial with beta-blockers, which had shown a positive effect on mortality in the 1980s, gave negative results, suggesting that some older treatment methods may have lost their significance. The review concludes that the residual risk of death after acute myocardial infarction remains high despite guideline compliance.
What is still missing is a fundamentally new treatment approach that can reduce the residual mortality risk. No drug repurposing candidate is identified in these abstracts. The negative results from recent large trials indicate that current trial designs and patient stratification have not yielded new effective therapies. Money and trial infrastructure are needed to develop and test genuinely novel methods, but no such method is described here.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Pharmacotherapy · 2003 · 1 citations
Thrombolytics: prospects for new agents
AbstractThrombolytic therapy revolutionised the management of acute myocardial infarction (AMI). The ability to re-establish coronary artery patency with intravenous thrombolytic drugs has transformed our therapeutic approach, despite patency failures and re-occlusions. However, the established agents are not perfect and a number of novel thrombolytic drugs have consequently been developed and evaluated. This article reviews the currently available agents, discusses available adjunctive therapies and examines the future developments that may affect the application of this therapy.
International Journal of Cardiovascular Sciences · 2020 · 1 citations · open access
Potential Role of Hematological Parameters in Patients with Acute Myocardial Infarction: viewpoint
AbstractAcute myocardial infarction (AMI) is one of the most important cardiovascular diseases, leading to disability and death worldwide. Atherosclerosis is the main etiology of AMI, which is characterized by a series of highly specific cellular and molecular responses that can best be described, in aggregate, as an inflammatory disease. Risk factors such as arterial hypertension, diabetes mellitus, smoking, dyslipidemia, obesity, emotional stress and family history are not, in themselves, sufficient for in-hospital risk assessment of patients with AMI. Recently, several [...]
Rational Pharmacotherapy in Cardiology · 2024 · 0 citations · open access
The evolution of evidence-based methods of acute myocardial infarction treatment: is there any reason for optimism in recent years?
AbstractThe article briefly describes the stages of creating the main methods of acute myocardial infarction (MI) and its complications treatment. It is noted that currently existing clinical guidelines (CG) were formed at the end of the first decade of the XXI century; since then there have been no principal changes in the CG due to the lack of fundamentally new approaches to the acute MI treatment, its immediate and long-term outcomes. Compliance with the current CG has significantly reduced hospital mortality in acute MI and improved long-term outcomes. However, today, despite compliance with the CG, the absolute hospital mortality rates for acute MI remain quite high, and the long-term prognosis of patients’ lives is very unfavorable. A number of major randomized clinical trials that ended in 2023-2024 and studied fundamentally new approaches to the treatment of acute MI and its long–term outcomes are analyzed. It is noted that none of these studies gave a positive result. A new study with beta-blockers, which proved its positive effect on the mortality of patients with acute MI in the 80s of the twentieth century, gave negative results. This may indicate that a number of acute MI treatment methods, the effectiveness of which was proven several decades ago, have now lost their significance. It is concluded that despite compliance with modern CG, the residual risk of death after acute MI remains quite high. It is necessary to develop principally new methods of treating this disease.
Expert Opinion on Pharmacotherapy · 2003 · 0 citations
Thrombolytics: prospects for new agents
AbstractThrombolytic therapy revolutionised the management of acute myocardial infarction (AMI). The ability to re-establish coronary artery patency with intravenous thrombolytic drugs has transformed our therapeutic approach, despite patency failures and re-occlusions. However, the established agents are not perfect and a number of novel thrombolytic drugs have consequently been developed and evaluated. This article reviews the currently available agents, discusses available adjunctive therapies and examines the future developments that may affect the application of this therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
